Search results for "Cytochrome P-450 CYP2B6"

showing 3 items of 3 documents

Re-expression of C/EBP alpha induces CYP2B6, CYP2C9 and CYP2D6 genes in HepG2 cells.

1998

Cytochrome P450 (CYP) activity is very low or even absent in human hepatomas, a phenomenon that is accompanied by low levels of some liver transcription factors, notably C/EBP alpha. To investigate a possible link between this transcription factor and hepatic CYP expression, we have stably transfected HepG2 cells with a C/EBP alpha vector containing a Zn-inducible metallothionein promoter. Expression of functional C/EBP alpha up to liver levels concomitantly increased the mRNAs of several members of the CYP2 family (2B6, 2C9 and 2D6), suggesting that this transcription factor may play a relevant role in controlling the hepatic expression of CYP enzymes.

Carcinoma HepatocellularCYP2B6BiophysicsHepG2 cellTransfectionBiochemistryGene Expression Regulation EnzymologicCytochrome P-450 Enzyme SystemStructural BiologyTumor Cells CulturedGeneticsHumansMetallothioneinRNA MessengerVector (molecular biology)Molecular BiologyTranscription factorGeneCells CulturedCytochrome P-450 CYP2C9biologyChemistryNuclear ProteinsCytochrome P450Oxidoreductases N-DemethylatingCell BiologyTransfectionMolecular biologyDNA-Binding ProteinsCytochrome P-450 CYP2B6C/EBPαCytochrome P-450 CYP2D6Steroid 16-alpha-HydroxylaseHepatocyte nuclear factor 4 alphaEnzyme InductionSteroid HydroxylasesCCAAT-Enhancer-Binding Proteinsbiology.proteinAryl Hydrocarbon HydroxylasesHuman hepatocyteCytochrome P450 gene regulationTranscription Factors
researchProduct

[Pharmacogenomics of antiretrovirals].

2008

HIV infection is a serious but treatable disease, yet current treatment is limited by development of resistance and high rates of adverse drug reactions. Antiretroviral therapy is especially suitable for pharmacogenomic investigation as both drug exposure and treatment response can be reliably measured. Increasing knowledge about genes implicated in pharmacokinetics, mode of action, efficacy, and toxicity of drugs has already provided relevant results for clinical practice, for example: The strong association of the abacavir hypersensitivity reaction with HLA-B*5701 permits testing patients for the allele, and if present avoiding the drug and therefore preventing the reaction. Persons with …

CyclopropanesDrugEfavirenzPyridinesmedia_common.quotation_subjectAtazanavir SulfateDiseaseBioinformaticsDrug HypersensitivityPatents as Topicchemistry.chemical_compoundPharmacokineticsCentral Nervous System DiseasesHLA AntigensAbacavirDrug Resistance ViralDrug DiscoveryMedicineHumansGenetic Predisposition to DiseasePharmacology (medical)Genetic TestingNevirapineGlucuronosyltransferaseDyslipidemiasHyperbilirubinemiamedia_commonRitonavirbusiness.industryPatient SelectionArea under the curveOxidoreductases N-DemethylatingGeneral MedicineDideoxynucleosidesBenzoxazinesHypersensitivity reactionCytochrome P-450 CYP2B6Infectious DiseaseschemistryAnti-Retroviral AgentsPharmacogeneticsAlkynesPharmacogenomicsAryl Hydrocarbon HydroxylasesbusinessOligopeptidesmedicine.drugMedicina clinica
researchProduct

Efavirenz and the CNS: what we already know and questions that need to be answered

2015

The NNRTI efavirenz has long been one of the most frequently employed antiretroviral drugs in the multidrug regimens used to treat HIV infection, in accordance with its well-demonstrated antiretroviral efficacy and favourable pharmacokinetics. However, growing concern about its adverse effects has sometimes led to efavirenz being replaced by other drugs in the initial treatment selection or to switching of therapy to efavirenz-free regimens in experienced patients. Neurological and neuropsychiatric reactions are the manifestations most frequently experienced by efavirenz-treated patients and range from transitory effects, such as nightmares, dizziness, insomnia, nervousness and lack of conc…

Microbiology (medical)DrugCentral Nervous SystemCyclopropanesPsychosismedicine.medical_specialtyEfavirenzAnti-HIV Agentsmedia_common.quotation_subjectHIV InfectionsPolymorphism Single Nucleotidechemistry.chemical_compoundimmune system diseasesCentral Nervous System DiseasesAntiretroviral Therapy Highly ActivemedicineAnimalsCytochrome P-450 Enzyme InhibitorsHumansPharmacology (medical)Adverse effectIntensive care medicineSuicidal ideationmedia_commonPharmacologybusiness.industryNeurotoxicityvirus diseasesmedicine.diseaseBenzoxazinesCytochrome P-450 CYP2B6Disease Models AnimalInfectious DiseaseschemistryPharmacogeneticsAlkynesReverse Transcriptase Inhibitorsmedicine.symptomCNSEfavirenzbusinessNeurocognitivePharmacogenetics
researchProduct